

**Current recommendations for vaccines against respiratory diseases in long-term care residents (aged ≥ 65 years)
or adults aged ≥ 65 years**

November 9, 2025

Vaccine	CDC recommendation from Adult Immunization Schedule	Post-Acute and Long-Term Care Medical Association (PALTmed) recommendation	Notes / Comments
2025-2026 COVID-19 vaccine (mRNA or non-mRNA formulation)	2 or more doses of vaccine for ALL adults aged ≥ 65 years, regardless of immune status.	All residents ≥ 18 years: One dose of 2025-2026 COVID-19 vaccine. - Moderna's "SPIKEVAX", Novavax's "NUVAXOVID", and Pfizer-BioNTech's "COMIRNATY", can be given at least 2 months after any prior COVID-19 vaccine dose. - Moderna's "MNEXSPIKE" can be given at least 3 months after any prior COVID-19 vaccine dose. Residents with moderate to severe immunocompromise: At least two doses of the 2025–2026 COVID-19 vaccine. Preferred interval between doses is 6 months, but they may be given as soon as 2 months apart if needed (e.g., during an outbreak).	- CDC: Recommends shared clinical decision making prior to COVID-19 immunization - CDC: no preference for mRNA or non-mRNA COVID-19 vaccine - CDC: Second dose recommended 6 months after first dose with minimum interval of 2 months - CDC: However, if Moderna's mNexspike vaccine used for Dose 1, second dose recommended at 6 months, with minimum interval of 3 months - PALTmed: no preference for one brand or type (mRNA/non-mRNA) of vaccine - See References below
2025-2026 Influenza vaccine	One dose of vaccine annually. One of the following three vaccines is recommended for adults aged ≥ 65 years: - Fluzone High-Dose (HD-IIV3) - Flublok (RIV3) - Fluad (aIIV3) CDC recommends vaccination ideally in September or October	As of Sept 2025, PALTmed working on evidence review and recommendations specific to 2025/2026 COVID-19 (completed), influenza, and RSV vaccines in the post-acute and long-term care population.	- CDC: No recommendation for shared decision making - HD-IIV3 = high-dose inactivated influenza vaccine, trivalent - RIV3 = recombinant influenza vaccine, trivalent - aIIV3 = adjuvanted inactivated influenza vaccine, trivalent - See References below
Respiratory Syncytial Virus (RSV) vaccine	For adults aged ≥ 75 years, only a single dose of one of the following three vaccines is recommended. Additional doses are NOT recommended. - Arexvy (GSK), or - Abrysvo (Pfizer), or - mResvia (Moderna) For adults aged 50-74 with at least one risk factor that increases risk for severe RSV disease, a single dose of an FDA-licensed vaccine is recommended. Additional doses are NOT recommended. Acceptable vaccines include: - Arexvy, or - Abrysvo, or - mResvia	As of Sept 2025, PALTmed working on evidence review and recommendations specific to 2025/2026 COVID-19 (completed), influenza, and RSV vaccines in the post-acute and long-term care population.	- CDC: Eligible adults can get an RSV vaccine at any time, but the best time to vaccinate patients is in late summer and early fall before RSV usually starts to spread in the community - CDC: No preference for one vaccine over another - Arexvy (GSK): FDA licensed for people aged 50-59 at increased risk for severe RSV disease, AND people aged 60 and older - Abrysvo (Pfizer): FDA-licensed for people aged 18-59 at increased risk for severe RSV disease, AND people aged 60 and older - mRESVIA (Moderna): FDA-licensed for people aged 18-59 at increased risk for severe RSV disease, AND for people aged 60 and older People who have received one dose of any RSV vaccine for any indication should NOT receive another dose. For now, this is a single dose vaccine. - See References below

References:

- Centers for Disease Control and Prevention. Adult Immunization Schedule by Age (Addendum updated August 7, 2025). Accessed at <https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html#table-age>. Dated Oct 7, 2025.
- Centers for Disease Control and Prevention. 2025-2026 COVID-19 Vaccination Guidance. Accessed at <https://www.cdc.gov/covid/hcp/vaccine-considerations/routine-guidance.html#heading-od-jmebm1w>. Dated Nov 4, 2025. See Section 1e.
- Centers for Disease Control and Prevention. Interim Clinical Considerations for Use of COVID-19 Vaccines in the United States. Accessed at <https://www.cdc.gov/covid/hcp/vaccine-considerations/index.html#toc>. Dated Nov 4, 2025.
- Post-Acute and Long-Term Care Medical Association. Recommendations for COVID-19 Vaccine in Post-Acute and Long-Term Care Residents and Staff. Accessed at https://paltmed.org/sites/default/files/2025-10/25-26%20COVID%20recommendations_FINAL.pdf. Dated 10/14/2025. *Note: Recommendations in table above only pertain to patients, not staff. See PALTmed document for more information.*
- Grohskopf LA, Blanton LH, Ferdinands JM, Reed C, Dugan VG, Daskalakis DC. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2025–26 Influenza Season. MMWR Morb Mortal Wkly Rep 2025;74:500–507. DOI: <http://dx.doi.org/10.15585/mmwr.mm7432a2>. Published online August 28, 2025.
- Centers for Disease Control and Prevention. RSV Vaccine Guidance for Adults. Accessed at https://www.cdc.gov/rsv/hcp/vaccine-clinical-guidance/adults.html#cdc_cg_special_populations_risks-recommendations. Dated July 8, 2025.
- Arexvy Prescribing Information. Accessed at https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Arexvy/pdf/AREXVY.PDF. Current revision 8/2025.
- Abrysvo Prescribing Information. Accessed at <https://labeling.pfizer.com/ShowLabeling.aspx?id=19589>. Current revision 7/2025.
- MRESVIA Prescribing Information. Accessed at https://static.modernatx.com/pm/6cef78f8-8dad-4fc9-83d5-d2fbb7cff867/36130c97-6fb0-4bea-9f2e-fb5be7a90729/36130c97-6fb0-4bea-9f2e-fb5be7a90729_viewable_rendition_v.pdf. Current revision 6/2025.